Company news

Amylyx Pharmaceuticals, Inc. news in 2026

Amylyx Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

November 5, 2026

Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

November 4, 2026

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences

November 3, 2026

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

November 2, 2026

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

October 6, 2026

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

September 23, 2026

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

September 8, 2026

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

August 19, 2026

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

August 18, 2026

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

August 18, 2026

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

August 17, 2026

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

August 3, 2026

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

June 22, 2026

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 8, 2026

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 15, 2026

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 7, 2026

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

May 5, 2026

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 29, 2026

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

March 23, 2026

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 2, 2026

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 23, 2026

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

January 7, 2026

Calls in 2026

Decks in 2026